Prevalence of Congestive Heart Failure Fuels Growth of Dilated Cardiomyopathy Therapeutics Market

Dilated cardiomyopathy (DCM) is a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. This condition is characterized by enlargement of ventricular chamber, thinning of heart walls and inability to sufficiently pump blood throughout the body. Dilated cardiomyopathy can develop at any age but is more common among people aged between 20 years to 60 years. Genetic inheritance is found to affect about 30% to 40% of the total DCM patients. Single gene mutations in either the structural proteins of the myocyte, such as dystrophin, metavinculin, and lamin, or of mitochondrial DNA are also a prominent cause of DCM. Other factors such as diabetes, thyroid disorder, alcoholism, viral infections of the heart and heart valve abnormalities can also lead to dilated cardiomyopathy. Moreover, according to the Pediatric Cardiomyopathy Registry, DCM occurs at a rate of 6 per million children. It is commonly diagnosed in younger children with an average age of diagnosis at 2 years.

Read the Comprehensive Overview of Dilated Cardiomyopathy Therapeutics Market: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Growing Incidence of Cardiac Diseases to Catapult Asia Pacific to Lead Position

The segment of angiotensin II receptor blockers led amongst other drug class segments in 2013. This was followed by the segment of beta blockers. The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy.

Geography-wise, the report segments the global dilated cardiomyopathy therapeutics market into: North America, Asia Pacific, Europe, and Rest of the World. North America stood as the leading regional market in 2013 mainly due to high incidence of cardiac diseases. Asia Pacific is expected to take the lead in the upcoming years as changing lifestyle resulting in increasing incidence of cardiac diseases propels growth of dilated cardiomyopathy therapeutics market.

Efforts to Develop Specific Drugs for Dilated Cardiomyopathy Propels Growth

The alarming rise in the prevalence of congestive heart failure is one of the prominent growth drivers of the global dilated cardiomyopathy market. Dilated cardiomyopathy accounts for 30-40% of total number of congestive heart failures each year. As per statistics of the World Health Organization, 17.5 million deaths in 2013 were related to heart disorders. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

Due to this, several companies have initiated to carry out clinical trials so as to develop drugs specifically for dilated cardiomyopathy. At present, there is not a single FDA approved drug specifically for dilated cardiomyopathy because of which treatment administered is the same as that for congestive heart failure. For example, Array BioPharma is carrying out phase II study for its drug ARRY-371797 for the treatment of dilated cardiomyopathy. In addition, in 2014, Celladon Corporation completed its phase II study of MYDICAR to be used for the treatment of dilated cardiomyopathy. Success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market.

Studies reveal that angiotensin receptor blockers such as valsartan can reduce probability of hospitalization by 28%. These drugs have also been effective for patients of systolic heart disease by reduction of deaths by 37% and also for reduced frequency of hospitalization. These factors are furthering the expansion of the global dilated cardiomyopathy therapeutics market.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

On the flip side, the side effects of dilated cardiomyopathy therapeutics is leading to their declined use. Moreover, availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Rising Incidences of Heart Failure will Boost Dilated Cardiomyopathy Therapeutics Market

Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.

Browse Complete Report Details at: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Heart failure is primarily caused by dilated cardiomyopathy (DCM). DCM commonly develops in people aged between 20 years and 60 years. DCM is one of the primary factors, which indicates the need of heart transplantation. Approximately 30% to 40% of people genetically inherit DCM. Factors such as thyroid disorders, diabetes, a viral infection in the heart valve, and alcoholism could cause DCM. As per the Pediatric Cardiomyopathy Registry, dilated cardiomyopathy affects 6 out of 1 million children. DCM is commonly diagnosed in young children, the common diagnosis age being 2 years.

The global dilated cardiomyopathy therapeutics market is segmented on the basis of region and drug class. Some of the commonly used drug classes in DCM treatment are aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and beta blockers. In 2013, the angiotensin II receptor blockers (ARBs) segment held the largest share in the global dilated cardiomyopathy therapeutics market. In 2013, the beta blockers segment was the second largest segment in the global dilated cardiomyopathy therapeutics market.

The increasing incidence of congestive heart failure is expected to drive the global dilated cardiomyopathy therapeutics market in the coming few years. DCM accounts for 30% to 40% of congestive heart failure cases every year, reports suggest. Considering the increasing incidence of congestive heart failure, leading players have started initiating many clinical trial studies for DCM. Going forward, a global rise in the number of heart failure cases is expected to increase the demand for effective treatments. This is expected to drive the global dilated cardiomyopathy therapeutics market in the near future. The global market is expected to be hampered by the rising availability of implantable devices and the side effects of DCM drugs.

Based on geography, the global dilated cardiomyopathy therapeutics market is divided into Asia Pacific, Europe, North America, and Rest of the World. In 2013, in terms of revenue, North America held a massive share in the global dilated cardiomyopathy therapeutics market due to the increasing acceptance of branded drugs and the increasing incidences of congestive heart failure here.

Get the Premium Research Report of Dilated Cardiomyopathy Therapeutics Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

Some of the key companies operating in the global dilated cardiomyopathy therapeutics market are Array BioPharma, Inc., Celladon Corporation, Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., Vericel Corporation, and AstraZeneca plc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/